7 October 2015 - CADTH has received notice of a pending resubmission for Xolair (omalizumab) for patients with severe peristent asthma. For information about the patient input process or for additional instructions, please see the patient input page of the CADTH website.

For more details, go to: https://www.cadth.ca/omalizumab-drug-plan-submission